Alterations in cell cycle control during tumor progression: effects on apoptosis and the response to therapeutic agents.
Muschel
R J
RJ
Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia 19104-6082, USA.
McKenna
W G
WG
D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D017209:Apoptosis / Q000187:drug effects / Q000235:genetics / Q000502:physiology*; D002453:Cell Cycle / Q000187:drug effects / Q000235:genetics / Q000502:physiology*; D002455:Cell Division; D050759:Cyclin-Dependent Kinase Inhibitor p21; D018844:Cyclin-Dependent Kinases / Q000037:antagonists & inhibitors / Q000502:physiology; D016213:Cyclins / Q000037:antagonists & inhibitors / Q000502:physiology; D004249:DNA Damage; D018450:Disease Progression; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D047908:Intracellular Signaling Peptides and Proteins; D009363:Neoplasm Proteins / Q000235:genetics / Q000502:physiology*; D009369:Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000473:pathology*; D011506:Proteins / Q000502:physiology; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000502:physiology; D016271:Proto-Oncogene Proteins c-myc / Q000502:physiology; D016159:Tumor Suppressor Protein p53 / Q000502:physiology; D000097642:GADD45 Proteins
D000970:Antineoplastic Agents; D050759:Cyclin-Dependent Kinase Inhibitor p21; D018844:Cyclin-Dependent Kinases; D016213:Cyclins; D047908:Intracellular Signaling Peptides and Proteins; D009363:Neoplasm Proteins; D011506:Proteins; D019253:Proto-Oncogene Proteins c-bcl-2; D016271:Proto-Oncogene Proteins c-myc; D016159:Tumor Suppressor Protein p53; D000097642:GADD45 Proteins; C493956:CDKN1A protein, human